Alzheimer’s and Memory Research
About Our Research
The Memory Disorders Program investigates new treatments designed to prevent and slow Alzheimer’s disease. Furthermore, we develop new tools to improve diagnostic and prognostic accuracy.
The Memory Disorders Program is actively recruiting subjects for clinical trials, volunteers are needed to participate in our research. Ongoing studies are those that are underway and are no longer recruiting new subjects.
- SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer’s Disease (AD) (SIGNAL-AD)
- Metformin in Alzheimer’s Dementia Prevention (MAP)
- A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer’s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (AHEAD 3-45 Study)
- Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3)
- Memory Improvement Through Nicotine Dosing (MIND) Study (MIND)
- DC Longitudinal Study on Aging and Specimen Bank– On Hold
- Dementia Screening using Automated Speech Analysis: A Follow Up to the Pilot Study
- TRC-PAD Program: In-Clinic Trial-Ready Cohort (TRC-PAD)
- Longitudinal Early-onset Alzheimer’s Disease Study Protocol (LEADS)
- A Study of JNJ-63733657 in Participants With Early Alzheimer’s Disease (Autonomy)
- A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer’s Disease (INVOKE-2)
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2)
- Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4)
- A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer’s Disease (Clarity AD)
- Longitudinal Evaluation of Amyloid Risk and Neurodegeneration – the LEARN Study (LEARN)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Gantenerumab Administration in Participants With Alzheimer’sDisease (AD) (PostGraduate)
- A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (EMBARK)
Joining Our Research
As the first step, we invite you to complete a pre-screening phone call. The call lasts 10-15 minutes, and you will be asked about your family and medical history, willingness to participate in research procedures, contact information and demographics. This one time call helps us determine your eligibility for research.
For more information on how to join our research program contact Carolyn Ward, Program Coordinator, at Phone: (202) 784-6671 or Email: email@example.com
Frequently Asked Questions
Please contact us if you have any specific questions.
It is not required that you be evaluated in our clinic prior to participating in research. If you have a diagnosis of mild cognitive impairment or Alzheimer’s disease and receive your medical care elsewhere, you may be eligible to participate. We ask that you request to have your medical records (including recent office visit notes, laboratory results and CT or MRI brain scan reports) sent to us.
Learn how to send us your medical records (see the Send Us Your Medical Records section).
Most studies require participants to have a study partner. Your study partner may be a family member or friend who will be asked to accompany you to study visits and to provide us with information about your health status throughout the study.
Some of our studies seek older adults who are cognitively normal, and those who have concerns about their memory. If this describes you, please contact us to learn more about possible research participation.
You may review the eligibility requirements for our Recruiting and Ongoing research studies through the web links provided above.
There is no fee to participate in research, and all study-related costs are covered by the research sponsor. In some cases, participants receive a small stipend to reimburse travel and other costs.
Please note that research sponsors will not pay for a clinical evaluation leading to a diagnosis. However, all study-related costs are covered by the research sponsor (such as the NIH or a pharmaceutical company), unless otherwise noted in the study consent form.
Each study has different procedures, therefore different risks. Common procedures include cognitive assessments, blood draws, spinal fluid draws, MRIs, PET scans, and experimental medication.
Additionally, we inform you of all the procedures and known risks when we invite to you participate in a study.
It is always a good idea to discuss possible participation in a clinical trial with your doctors for their advice and guidance.
The Georgetown University Institutional Review Board (IRB) oversees the research at the Memory Disorders Program. If you have questions about your rights as a Research Participant, or would like to file a complaint, you may contact the IRB at (202) 687-1506.
Participating in Clinical Trials: What You Need to Know by Christine Weber, PhD and Mary Sano, PhD of the Gertrude H. Sergievsky Center at Columbia University.